Brain and Central Nervous System Tumors — Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Citation(s)
A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment